Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

CHOLECOVID Collaborative; Harry V M Spiers; Omar Kouli; Waheed U Ahmed; Rebecca Varley; Daniel Ahari; Leah Argus; Kenneth A McLean; Sivesh K Kamarajah; Peter Coe; Ewen A Griffiths; Anthony KC Chan; Christian Macutkiewicz; Saurabh Jamdar; Michael Wilson; Catherine Fullwood; Giles Toogood; Ajith Siriwardena; Omar Kouli; Kenneth McLean; Catherine Fullwood; Daniel Ahari; Leah Argus; Rebecca Varley; Harry V M Spiers; Omar Kouli; Waheed Ahmed; Andrew Gilchrist; Matthew Goldsworthy; Majid Rashid; P Pockney; J Varela; N Brindl; J Ramirez; C Marafante; Y Iwao; A Ghzawi; M Elhadi; H Gacaferi; C Varghese; A Adeyeye; O Alser; C Teh; M Prieto; A Hasan; H Al-Naggar; R Salgado; F Veracierto; T Lancelotti; D Solinas; R Oddi

doi:10.1093/bjsopen/zrac052

Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

CHOLECOVID Collaborative^* (Corresponding Author), Harry V M Spiers^* (Corresponding Author), Omar Kouli^* (Corresponding Author), Waheed U Ahmed, Rebecca Varley, Daniel Ahari, Leah Argus, Kenneth A McLean, Sivesh K Kamarajah, Peter Coe, Ewen A Griffiths, Anthony KC Chan, Christian Macutkiewicz, Saurabh Jamdar, Michael Wilson, Catherine Fullwood, Giles Toogood, Ajith Siriwardena, Omar Kouli, Kenneth McLeanCatherine Fullwood, Daniel Ahari, Leah Argus, Rebecca Varley, Harry V M Spiers, Omar Kouli, Waheed Ahmed, Andrew Gilchrist, Matthew Goldsworthy, Majid Rashid, P Pockney, J Varela, N Brindl, J Ramirez, C Marafante, Y Iwao, A Ghzawi, M Elhadi, H Gacaferi, C Varghese, A Adeyeye, O Alser, C Teh, M Prieto, A Hasan, H Al-Naggar, R Salgado, F Veracierto, T Lancelotti, D Solinas, R Oddi

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

5 Downloads (Pure)

Abstract

Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic.
Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality.
Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121).
Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic.

Original language	English
Article number	zrac052
Number of pages	13
Journal	BJS Open
Volume	6
Issue number	3
Early online date	4 May 2022
DOIs	https://doi.org/10.1093/bjsopen/zrac052
Publication status	Published - Jun 2022

Bibliographical note

There was no funding support for this study.

Disclosure. The authors declare no conflict of interest.

Data Availability Statement

Anonymized source data can be made available on request.

Access to Document

10.1093/bjsopen/zrac052Licence: CC BY

CHOLECOVID_etal_BJSO_GlobalOverviewoftheManagement_VOR
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. http://creativecommons.org/licenses/by/4.0/
Final published version, 569 KBLicence: CC BY

Cite this

Collaborative, CHOLECOVID., Spiers, H. V. M., Kouli, O., Ahmed, W. U., Varley, R., Ahari, D., Argus, L., McLean, K. A., Kamarajah, S. K., Coe, P., Griffiths, E. A., Chan, A. KC., Macutkiewicz, C., Jamdar, S., Wilson, M., Fullwood, C., Toogood, G., Siriwardena, A., Kouli, O., ... Oddi, R. (2022). Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study). BJS Open, 6(3), Article zrac052. https://doi.org/10.1093/bjsopen/zrac052

Collaborative, CHOLECOVID, Spiers, HVM, Kouli, O, Ahmed, WU, Varley, R, Ahari, D, Argus, L, McLean, KA, Kamarajah, SK, Coe, P, Griffiths, EA, Chan, AKC, Macutkiewicz, C, Jamdar, S, Wilson, M, Fullwood, C, Toogood, G, Siriwardena, A, Kouli, O, McLean, K, Fullwood, C, Ahari, D, Argus, L, Varley, R, Spiers, HVM, Kouli, O, Ahmed, W, Gilchrist, A, Goldsworthy, M, Rashid, M, Pockney, P, Varela, J, Brindl, N, Ramirez, J, Marafante, C, Iwao, Y, Ghzawi, A, Elhadi, M, Gacaferi, H, Varghese, C, Adeyeye, A, Alser, O, Teh, C, Prieto, M, Hasan, A, Al-Naggar, H, Salgado, R, Veracierto, F, Lancelotti, T, Solinas, D & Oddi, R 2022, 'Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)', BJS Open, vol. 6, no. 3, zrac052. https://doi.org/10.1093/bjsopen/zrac052

@article{aa55a01136ee4735b48112c34735f061,

title = "Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)",

abstract = "Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic. ",

author = "CHOLECOVID Collaborative and Spiers, {Harry V M} and Omar Kouli and Ahmed, {Waheed U} and Rebecca Varley and Daniel Ahari and Leah Argus and McLean, {Kenneth A} and Kamarajah, {Sivesh K} and Peter Coe and Griffiths, {Ewen A} and Chan, {Anthony KC} and Christian Macutkiewicz and Saurabh Jamdar and Michael Wilson and Catherine Fullwood and Giles Toogood and Ajith Siriwardena and Omar Kouli and Kenneth McLean and Catherine Fullwood and Daniel Ahari and Leah Argus and Rebecca Varley and Spiers, {Harry V M} and Omar Kouli and Waheed Ahmed and Andrew Gilchrist and Matthew Goldsworthy and Majid Rashid and P Pockney and J Varela and N Brindl and J Ramirez and C Marafante and Y Iwao and A Ghzawi and M Elhadi and H Gacaferi and C Varghese and A Adeyeye and O Alser and C Teh and M Prieto and A Hasan and H Al-Naggar and R Salgado and F Veracierto and T Lancelotti and D Solinas and R Oddi",

note = "There was no funding support for this study. Disclosure. The authors declare no conflict of interest.",

year = "2022",

month = jun,

doi = "10.1093/bjsopen/zrac052",

language = "English",

volume = "6",

journal = "BJS Open",

issn = "2474-9842",

publisher = "Oxford University Press (OUP)",

number = "3",

}

TY - JOUR

T1 - Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

AU - Collaborative, CHOLECOVID

AU - Spiers, Harry V M

AU - Kouli, Omar

AU - Ahmed, Waheed U

AU - Varley, Rebecca

AU - Ahari, Daniel

AU - Argus, Leah

AU - McLean, Kenneth A

AU - Kamarajah, Sivesh K

AU - Coe, Peter

AU - Griffiths, Ewen A

AU - Chan, Anthony KC

AU - Macutkiewicz, Christian

AU - Jamdar, Saurabh

AU - Wilson, Michael

AU - Fullwood, Catherine

AU - Toogood, Giles

AU - Siriwardena, Ajith

AU - Kouli, Omar

AU - McLean, Kenneth

AU - Fullwood, Catherine

AU - Ahari, Daniel

AU - Argus, Leah

AU - Varley, Rebecca

AU - Spiers, Harry V M

AU - Kouli, Omar

AU - Ahmed, Waheed

AU - Gilchrist, Andrew

AU - Goldsworthy, Matthew

AU - Rashid, Majid

AU - Pockney, P

AU - Varela, J

AU - Brindl, N

AU - Ramirez, J

AU - Marafante, C

AU - Iwao, Y

AU - Ghzawi, A

AU - Elhadi, M

AU - Gacaferi, H

AU - Varghese, C

AU - Adeyeye, A

AU - Alser, O

AU - Teh, C

AU - Prieto, M

AU - Hasan, A

AU - Al-Naggar, H

AU - Salgado, R

AU - Veracierto, F

AU - Lancelotti, T

AU - Solinas, D

AU - Oddi, R

N1 - There was no funding support for this study. Disclosure. The authors declare no conflict of interest.

PY - 2022/6

Y1 - 2022/6

N2 - Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic.

AB - Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic.

UR - http://dx.doi.org/10.1093/bjsopen/zrac052

U2 - 10.1093/bjsopen/zrac052

DO - 10.1093/bjsopen/zrac052

M3 - Article

SN - 2474-9842

VL - 6

JO - BJS Open

JF - BJS Open

IS - 3

M1 - zrac052

ER -

Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

Abstract

Bibliographical note

Data Availability Statement

Access to Document

Other files and links

Fingerprint

Cite this